{"title":"对 \"类癌综合征的疗效、安全性和不断发展的医学疗法尚未满足的需求 \"的更正","authors":"","doi":"10.1111/jne.13361","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Koumarianou, A</span>, <span>Daskalakis, K</span>, <span>Tsoli, M</span>, <span>Kaltsas, G</span>, <span>Pavel, M</span>. <span>Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome</span>. <i>J Neuroendocrinol.</i> <span>2022</span>; <span>34</span>(<span>7</span>):e13174. doi:10.1111/jne.13174\n </p><p>An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.</p><p>We sincerely apologize for any confusion this may have caused.</p>","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":"36 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jne.13361","citationCount":"0","resultStr":"{\"title\":\"Correction to “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”\",\"authors\":\"\",\"doi\":\"10.1111/jne.13361\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>\\n <span>Koumarianou, A</span>, <span>Daskalakis, K</span>, <span>Tsoli, M</span>, <span>Kaltsas, G</span>, <span>Pavel, M</span>. <span>Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome</span>. <i>J Neuroendocrinol.</i> <span>2022</span>; <span>34</span>(<span>7</span>):e13174. doi:10.1111/jne.13174\\n </p><p>An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.</p><p>We sincerely apologize for any confusion this may have caused.</p>\",\"PeriodicalId\":16535,\"journal\":{\"name\":\"Journal of Neuroendocrinology\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jne.13361\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuroendocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jne.13361\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.13361","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Correction to “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”
Koumarianou, A, Daskalakis, K, Tsoli, M, Kaltsas, G, Pavel, M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol.2022; 34(7):e13174. doi:10.1111/jne.13174
An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.
We sincerely apologize for any confusion this may have caused.
期刊介绍：
Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field.
In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
